Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell

Details for Australian Patent Application No. 2007203335 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Pachuk, Catherine J; Satishchandran, C; Giordano, Tony

Agent Griffith Hack

Pub. Number AU-B-2007203335

Parent 785395

Filing date 18 July 2007

Wipo publication date 9 August 2007

Acceptance publication date 7 July 2011

International Classifications

C12N 15/10 (2006.01) Mutation or genetic engineering - Processes for the isolation, preparation or purification of DNA or RNA

Event Publications

2 August 2007 Complete Application Filed

9 August 2007 Application Open to Public Inspection

  Published as AU-B-2007203335

25 October 2007 Assignment before Grant

  Nucleonics, Inc.; Message Pharmaceuticals, Inc. The application has been assigned to Nucleonics, Inc.

19 March 2009 Assignment before Grant

  Nucleonics, Inc. The application has been assigned to Alnylam Pharmaceuticals, Inc.

7 July 2011 Application Accepted

  Published as AU-B-2007203335

3 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007203336-Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof

2007203334-A gaming machine